Nivatrotamab

{
  "id": "MLC-T-ONC-015521",
  "term": "Nivatrotamab",
  "field": "Oncology and biomedicine",
  "definition": "A bispecific antibody comprised of a humanized anti-CD3 OKT3 (huOKT3) single chain variable fragment (scFv), linked to the carboxyl end of a humanized anti-GD2 3F8 (hu3F8) immunoglobulin G1 (IgG1) light chain, with potential antineoplastic activity. Upon intravenous administration, nivatrotamab binds to CD3 on T cells and disialoganglioside GD2 expressed on certain tumor cells, thereby cross-linking T cells with GD2-expressing tumor cells. This promotes a selective cytotoxic T-lymphocyte (CTL) response against GD2-expressing cells. The Fc region of the anti-GD2 hu3F8/anti-CD3 huOKT3 bispecific antibody has two amino acid substitutions, N297A and K322A, which may prevent cytokine release syndrome and other unwanted side effects including complement-mediated pain. GD2, a disialoganglioside and tumor-associated antigen (TAA), is overexpressed in a variety of tumor cell types. CD3 is part of the functional T-cell receptor (TCR) complex, which is necessary for antigen recognition by T cells and is required for signal transduction.",
  "abbreviation": "hu3F8-BsAb",
  "synonyms": [
    "humanized anti-GD2 x anti-CD3 bispecific antibody",
    "humanized 3F8 bispecific antibody",
    "hu3F8 x huOKT3 bispecific antibody",
    "anti-GD2 hu3F8/anti-CD3 huOKT3 bispecific antibody"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/nivatrotamab/"
}